Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung

Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung

<p>Supplementary Tables</p>

Сохранить в:

Библиографические подробности
Главный автор:	Koichi Tomoshige (15304682) (author)
Другие авторы:	William D. Stuart (15304685) (author), Iris M. Fink-Baldauf (15304688) (author), Masaoki Ito (15304691) (author), Tomoshi Tsuchiya (15304694) (author), Takeshi Nagayasu (15304697) (author), Tomoki Yamatsuji (15304700) (author), Morihito Okada (15038418) (author), Takuya Fukazawa (15304703) (author), Minzhe Guo (15304706) (author), Yutaka Maeda (15304709) (author)
Опубликовано:	2025
Предметы:	Cancer Cancer Biology Molecular and Cellular Biology Gene Regulation Promoter/enhancer analysis Lung Cancer Oncogenes & Tumor Suppressors Kras
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!

Схожие документы

Supplementary Tables from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
по: Craig M. Goodwin (14955973)
Опубликовано: (2025)

Figure S1 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
по: Craig M. Goodwin (14955973)
Опубликовано: (2025)

Figure S1 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
по: Craig M. Goodwin (14955973)
Опубликовано: (2025)

Figure S1 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
по: Craig M. Goodwin (14955973)
Опубликовано: (2025)

Figure S1 page4 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
по: Craig M. Goodwin (14955973)
Опубликовано: (2025)

Figure S2 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
по: Craig M. Goodwin (14955973)
Опубликовано: (2025)

Figure S2 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
по: Craig M. Goodwin (14955973)
Опубликовано: (2025)

Figure S2 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
по: Craig M. Goodwin (14955973)
Опубликовано: (2025)

Figure S3 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
по: Craig M. Goodwin (14955973)
Опубликовано: (2025)

Figure S3 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
по: Craig M. Goodwin (14955973)
Опубликовано: (2025)

Figure S4 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
по: Craig M. Goodwin (14955973)
Опубликовано: (2025)

Figure S4 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
по: Craig M. Goodwin (14955973)
Опубликовано: (2025)

Figure S5 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
по: Craig M. Goodwin (14955973)
Опубликовано: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
по: Craig M. Goodwin (14955973)
Опубликовано: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
по: Craig M. Goodwin (14955973)
Опубликовано: (2025)

Figure S5 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
по: Craig M. Goodwin (14955973)
Опубликовано: (2025)

Figure S6 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
по: Craig M. Goodwin (14955973)
Опубликовано: (2025)

Figure S6 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
по: Craig M. Goodwin (14955973)
Опубликовано: (2025)

Figure S7 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
по: Craig M. Goodwin (14955973)
Опубликовано: (2025)

Figure S7 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
по: Craig M. Goodwin (14955973)
Опубликовано: (2025)

Figure S7 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
по: Craig M. Goodwin (14955973)
Опубликовано: (2025)

Figure 1 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
по: Nicholas T. Younger (14956251)
Опубликовано: (2025)

Figure 2 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
по: Nicholas T. Younger (14956251)
Опубликовано: (2025)

Figure 3 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
по: Nicholas T. Younger (14956251)
Опубликовано: (2025)

Figure 4 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
по: Nicholas T. Younger (14956251)
Опубликовано: (2025)

Supplementary Table 1 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
по: Dhruv Chachad (14954640)
Опубликовано: (2025)

Supplementary Table 2 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
по: Dhruv Chachad (14954640)
Опубликовано: (2025)

Supplementary Table 3 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
по: Dhruv Chachad (14954640)
Опубликовано: (2025)

Supplementary Table 4 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
по: Dhruv Chachad (14954640)
Опубликовано: (2025)

Supplementary Table 5 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
по: Dhruv Chachad (14954640)
Опубликовано: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
по: Man Xu (14963249)
Опубликовано: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
по: Man Xu (14963249)
Опубликовано: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
по: Man Xu (14963249)
Опубликовано: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
по: Man Xu (14963249)
Опубликовано: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
по: Man Xu (14963249)
Опубликовано: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
по: Man Xu (14963249)
Опубликовано: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
по: Man Xu (14963249)
Опубликовано: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
по: Man Xu (14963249)
Опубликовано: (2025)

Supplementary Table S3 from Loss of <i>CDKN2A</i> Cooperates with <i>WWTR1(TAZ)–CAMTA1</i> Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
по: Caleb N. Seavey (15056489)
Опубликовано: (2025)

Supplementary Table S4 from Loss of <i>CDKN2A</i> Cooperates with <i>WWTR1(TAZ)–CAMTA1</i> Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
по: Caleb N. Seavey (15056489)
Опубликовано: (2025)

Cannot write session to /tmp/vufind_sessions/sess_45h6ustlc4gmlvjf3jo5co3svr